Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07520110 · ClinicalTrials.gov registry record · Phase 3
Metformin to Attenuate Progressive Respiratory Decline in Idiopathic Pulmonary Fibrosis
A Phase 3 study, sponsored by University of Massachusetts, Worcester.
- Not yet
- Registry status
- Phase 3
- Development phase
- 800
- Enrollment target
NCT07520110: Clinical Trial Phase 3 study, sponsored by University of Massachusetts, Worcester.
NCT07520110 is a Phase 3 study that has not yet begun recruiting, run by University of Massachusetts, Worcester. The registered enrollment target is 800 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07520110, a Phase 3 study, has not yet begun recruiting, sponsored by University of Massachusetts, Worcester.
- NOT YET RECRUITING
- Registry status
- Phase 3
- Development phase
- 800 participants
- Enrollment target
Study Summary
This is a randomized, placebo-controlled trial of metformin in 400 participants with idiopathic pulmonary fibrosis (IPF) who are at high risk of adverse clinical outcomes based on a proteomic classifier. The primary objective is to assess the safety and efficacy of metformin compared to placebo in participants with IPF who are at high-risk for adverse clinical events. Approximately 800 participants with IPF will be screened. 400 participants who are at high risk for adverse clinical events (proteomic signature present) will be randomized into receiving metformin (n\~200) or matching placebo (n\~200). Participants that meet the eligibility criteria but do not have the proteomic signature (proteomic signature absent) will be contacted by phone at 12 and 24 months to review medical history.
Primary Outcome
Clinical composite measure defined as the time from randomization to the first occurrence of any of its three components: all-cause mortality, first unplanned (non-elective) hospitalization, or lung transplantation.
Interventions
- DRUG Metformin
- DRUG Matching Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 800 participants |
| Start Date | 2026-08-01 |
| Est. Completion | 2029-03-15 |
| Phase | Phase 3 |
What is known before NCT07520110 opens enrollment
NCT07520110 is an interventional study that assigns participants to a tested intervention. The registered 800 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which Metformin is the first listed.
NCT07520110 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07520110 about?
NCT07520110 is a clinical study titled "Metformin to Attenuate Progressive Respiratory Decline in Idiopathic Pulmonary Fibrosis". This is a randomized, placebo-controlled trial of metformin in 400 participants with idiopathic pulmonary fibrosis (IPF) who are at high risk of adverse clinical outcomes based on a proteomic classifier. The primary objective is to assess the safety and efficacy of metformin compared to placebo in p...
What is the current status of trial NCT07520110?
This trial is currently not yet recruiting. It is a Phase 3 study. The enrollment target is 800 participants. The study started on 2026-08-01. Estimated completion is 2029-03-15.
What interventions are being tested in trial NCT07520110?
The interventions under investigation include: Metformin (DRUG), Matching Placebo (DRUG).
Who is sponsoring clinical trial NCT07520110?
This trial is sponsored by University of Massachusetts, Worcester, which has 240 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07520110's enrollment target sits among peer trials
800 414th of 2000 higher than 1,573 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00695214 · 800 participants · Phase 2
Drug-Induced Sleep Endoscopy for Upper Airway Evaluation in Obstructive Sleep Apnea
- NCT03048201 · 800 participants · NA
Physica System Total Knee Replacement Registry Study
- NCT03792659 · 800 participants
The EXPLORE MG Registry for Myasthenia Gravis
- NCT03819296 · 800 participants · Phase 1
Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI